Strezam (etifoxin hydrochloride) capsules 50 mg. №60

Description

Strezam (etifoxin hydrochloride) capsules 50 mg. №60

Composition

active substance: etifoxin hydrochloride;

1 capsule contains ethifoxin hydrochloride 50 mg;

excipients: lactose monohydrate; talc; microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate;

capsule shell: titanium dioxide (E 171); indigotine (E 132); gelatin.

Dosage form

Capsules.

Main physical and chemical properties: № 2 capsules with blue lid and opaque white body, containing white powder.

Pharmacotherapeutic group

Drugs acting on the nervous system. Psycholeptics. Anxiolytics. Other anxiolytics. Etifoxin.
ATX code N05B X03.

Pharmacological properties

In therapeutic doses of etifoxin hydrochloride exhibits anxiolytic properties and has a neurovegetative regulatory effect.

In vitro and in vivo animal studies have shown that the anxiolytic effect of etifoxin is due to a dual mechanism of action (direct and indirect) on the GABA receptor to increase GABA-ergic transmission:

• direct effect on the GABA receptor due to positive allosteric modulation by binding mainly to β2 or β3 subunits;
• indirect effects due to increased production of neurosteroids in the brain (by activating mitochondrial translocation of proteins), including allopregnanolone, which are positive allosteric modulators of the GABA receptor.

Indications

Strezam is used in the treatment of patients suffering from neurotic conditions caused by stress and accompanied by causeless anxiety, anxiety-phobic disorders, fear, loss of vitality, apathy, autonomic disorders and decreased physical activity.

Contraindications

The appointment of Strezam is avoided if the patient has individual hypersensitivity to etifoxine hydrochloride, galactosemia, insufficient production of lactose, or glucose-galactose malbsorption syndrome.
Strezam is not used to treat patients in shock, severe liver and kidney dysfunction, as well as myasthenia gravis. The drug should not be used in pediatric practice, for the treatment of pregnant and lactating women.
With extreme caution, the drug should be taken by those who operate potentially dangerous machinery or drive various vehicles.

Application during pregnancy and lactation

Strezam is not used to treat pregnant and lactating women. If the onset of pregnancy coincides with treatment with etifoxine hydrochloride, then it is recommended to stop taking the drug and replace it with any alternative agent. When Stresam is prescribed during lactation, breastfeeding is stopped.

Method of administration and dosage

Strezam is an oral preparation: its capsules are swallowed whole before meals and washed down with a small amount of water. The doctor determines the duration of treatment and the dose of the drug independently based on the severity of the disease. If there are no other recommendations, the patient should take 1 capsule 2 or 3 times a day. Duration of treatment is from 4 to 12 weeks.
After stopping treatment with Strezam, the withdrawal syndrome does not develop.

Overdose

Stresam in high doses causes a decrease in blood pressure.
To stabilize the patient’s condition, he is prescribed a gastric lavage, provides the intake of enterosorbents and drugs that normalize pressure.

Side effects

Taking Strezam is very rarely accompanied by the development of side effects. In some cases, in the first days of treatment with the drug, the patient may experience slight dizziness, which does not require specific treatment or discontinuation of the drug. With continued treatment, the patient’s body adapts to the drug and the dizziness disappears.
If the patient suffers from an increased allergenic background, then taking the drug can cause him to develop various allergic reactions, manifested by itching, rashes, erythema and urticaria.